Home › Compare › VGMIF vs ABBV
VGMIF yields 1333.33% · ABBV yields 3.06%● Live data
📍 VGMIF pulled ahead of the other in Year 1
Combined, VGMIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VGMIF + ABBV for your $10,000?
Visible Gold Mines Inc. acquires and explores for gold mineral deposits in Canada. The company holds a 100% interest in the Cadillac project comprising 145 mining claims covering approximately 5,000 hectares located in west of Rouyn-Noranda, Québec; the Piko property covering 26 mining claims situated in Abitibi-Témiscamingue in Québec; and the Veronik gold property that consists of 78 mining claims located in southeast of Hecla's Casa Berardi gold mine. In addition, it holds interest in the Horsefly Property with 175 mining claims covering an area of 6,050 hectares located in the Druillettes and Gradis townships; the Doda project that consists of 25 mining claims covering an area of approximately 1,400 hectares located in Québec; the Dovercliff property, which consists of 3 mining claims located in the Rouyn-Noranda, Québec; and the Phooey Lake property, which include 75 mining claims located in the Chibougamau, Québec. The company also holds a 100% interest in the MegaLi Project consisting of 78 mining claims covering an area of 3,996 hectares; and the NataLi Project comprising of 107 mining claims covering an area of 5,667 hectares located in the region of James Bay, Québec. Visible Gold Mines Inc. was incorporated in 2007 and is based in Rouyn-Noranda, Canada.
Full VGMIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.